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Introduction
Autoantibody signatures have provided invaluable information 
for assisting both in the identification and early detection of 
disease.1–4 Furthermore autoantigens, such as anaplastic lym-
phoma kinase (ALK), which are functionally implicated in 
tumor progression, represent important therapeutic targets.5,6
In a previous study, protein microarrays were screened with 
sera from lymphoma patients to identify lymphoma-associated 
antigens. The aim was to identify autoantigens that might 
represent new tools for identifying high risk patients and/
or novel treatment options for patients with systemic 
ALK-negative anaplastic large cell lymphoma (ALCL), 
a provisional tumor entity with a poor prognostic outlook. The 
FAS-associated protein with death domain (FADD), encoded 
by a gene within 11q13, was identified as an autoantigen rec-
ognized by circulating antibodies present not only in the sera 
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of patients with systemic ALCL but also in patients with 
peripheral T-cell lymphoma, not otherwise specified (PTCL, 
NOS), as well as B-cell lymphoma.7 PTCL, in common with 
systemic ALK-negative ALCL, represents a poorly defined 
lymphoma category with a poor prognostic outlook for which 
improved therapies are urgently required.8
Multiple roles have been ascribed to the FADD protein. 
Containing a death domain (DD) and a death effector 
domain (DED), FADD is a major adaptor protein in the 
extrinsic apoptotic pathway linking transduction signals from 
membrane-bound death receptors, eg, CD95 and DR4, with 
caspase 8.9,10 More recently, interactions of FADD with RIP1 
and RIP3 have been identified, with FADD being a negative 
regulator of a programmed form of necrotic cell death, known 
as “necrotopsis.”11,12 FADD is also required for embryogen-
esis and lymphocyte proliferation via pathways that are inde-
pendent of death receptor-mediated apoptosis,13–16 the DD 
motif acting as a switch between apoptosis and proliferation.16 
The pivotal roles of FADD in cell cycle regulation and 
proliferation17,18 occur following its phosphorylation (at serine 
194 in humans or serine 171 in mice) and nuclear relocaliza-
tion at the G2/M stage of cell cycle.19 Nuclear pFADD may 
also be involved in gene surveillance through its regulation 
with human telomerase reverse transcriptase20 and its asso-
ciation with complexes containing the DNA repair molecules 
MBD4 and MLH1.21
FADD has been associated with disease development in 
humans.22–25 The amplification of the FADD gene and its cor-
relation with increased FADD protein expression in head and 
neck cancers led Gibcus et al. to describe FADD as a possible 
key gene of functional interest in the 11q13 amplicon.26 Con-
flicting evidence has, however, been obtained on the relevance 
of high levels of pFADD to patient outcome in a number of 
solid tumors such as head and neck cancer,26,27 adenocarci-
noma,22,28 gastric cancer,29 and prostate cancer.20 Higher levels 
of pFADD were, however, found to increase chemosensitiza-
tion in prostate cancer cells23,30 and HeLa xenografts.31
Of relevance to the current study is that chromosomal 
abnormalities of the 11q13 region, other than those associated 
with Cyclin D1, have also been linked to hematological malig-
nancies32,33 thus increasing the possibility of the involvement 
of FADD in these tumor types. Since pFADD has also been 
reported to correlate with proliferation in a range of B-cell 
non-Hodgkin lymphomas (NHLs),34 the current immuno-
histochemical study on the detection of pFADD focuses on 
T-cell malignancies to determine its potential relevance as a 
therapeutic target in these tumors.
Materials and Methods
tissue samples. Normal tissues: Fresh tonsil was obtained 
from patients attending the Ear, Nose and Throat Depart-
ment, John Radcliffe Hospital, Oxford. Paraffin-embedded 
normal tissues were obtained from the Centro Nacional de 
Investigaciones Oncologicas (CNIO), Madrid.
Hematological malignancies: Tissue microarrays (TMAs) 
of a variety of lymphomas were obtained from the CNIO 
while TMAs of ALK-positive and ALK-negative ALCL 
and PTCL were obtained from the Department of Pathol-
ogy, Wüerzburg. The 39 B-cell lymphomas consisted of 
the following cases: diffuse large B-cell (DLBCL, n = 9), 
mantle cell lymphoma (MCL, n = 7), follicular lymphoma 
(FL, n = 7), Burkitt’s lymphoma (BL, n = 6), and Hodgkin’s 
lymphoma (HL, n = 10). The 227 T-cell tumors consisted of 
the following cases: PTCL (NOS) (n = 89), ALK-positive 
ALCL (n = 38), ALK-negative ALCL (n = 54), angioimmu-
noblastic lymphoma (AITL, n = 15), angiocentric lymphoma 
(n = 5), T-cell lymphoblastic lymphoma (TCL, n = 7), cuta-
neous T-cell lymphoma (CTCL, n = 3), T/NK lymphoma 
(n = 2), mycosis fungoides (MF, n = 6), and T-cell intestinal 
lymphoma (n = 8).
All normal and neoplastic cells and tissues were 
obtained only after ethical approval and informed consent 
had been given.
cell lines. The Thiel (myeloma), SUDHL-1, Karpas 299 
(ALK-positive ALCL), FEPD (ALK-negative ALCL). Jurkat 
and CEM (T-acute lymphoblastic leukemia), U937 and HL60 
(acute myeloid leukemia), germinal center – SUDHL-6, 
Table 1. expression of pFaDD in normal cells and tissues.
TIssuE *pFADD DIsTRIbuTIOn
hematopoietic
Bone marrow megakaryocytes and occasional large blast 
cells
tonsil epithelium, subpopulations of germinal  
center B-cells, tingible body macrophages  
and subpopulations of interfollicular t and  
B cells 
thymus subpopulations of B cells, macrophages,  
epithelium, and scattered t cells
non-hematopoietic
Brain no labeling detected
thyroid occasional nucleus of epithelial cells
Lung no labeling detected
Breast no labeling detected
Colon subset of crypt epithelial cells
Liver occasional hepatocyte
kidney occasional cell in tubule
Pancreas acinar and islet cells
Fallopian tubes subset of epithelial cells
Uterus scattered epithelial cells
testis majority of spermatogonia and weak  
labeling of Leydig cells.
Placenta scattered syncitiotrophoblast
Prostate subset of epithelial cells
Bladder epithelial cells
note: *nuclear staining.
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Figure 1. immunolabeling studies to show pFaDD protein expression in tonsil (A–F) and thymus (g–J).  
notes: tonsil: (A) single immunoperoxidase labeling shows heterogeneity of pFaDD expression in the nuclei of subpopulations of tonsil cells. strong 
labeling is present in a subpopulation of germinal center (gc) cells (arrowed). scattered cells with weaker labeling are present in the mantle zone (mz) 
and interfollicular (if) areas. (b) it can be seen from the double immunoperoxidase labeling studies that pFaDD (brown) is heterogeneously expressed 
in the majority of CD20-positive (blue) germinal center B cells (arrowed) but (C) absent from the majority of CD3-positive (blue) t cells in the germinal 
center (inset, arrowed) and (D) interfollicular areas (inset, arrowed). (E) nuclear pFaDD expression (brown) is also present in the occasional CD68-
positive tingible body macrophage (blue, arrowed) while (F) pFaDD was not detected in the interfollicular CD68-positive macrophages (arrowed). 
thymus: From (g) it can be seen that the expression of pFaDD is heterogenous and limited to subpopulations of cells (arrowed) in the thymic medulla 
(med) and cortex (cor). (h) pFaDD was undetectable in the majority of the CD3-positive 9blue) thymocytes (inset, arrowed), pFaDD was undetectable 
in the majority of the CD3-positive (blue) thymocytes (inset, arrowed). (I) strong pFaDD expression (brown) was, however, detected in (I) some CD20-
positive B cells (blue, arrowed), (J) CD68-positive macrophages (blue, arrowed), and (K) the cytokeratin-positive (blue) thymic epithelial cells (inset, 
arrowed).
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Table 2. pFaDD protein expression in cell lines derived from 
hematological malignancies.
CELL LInE *pFADD
T-cell
FePD nuclei ++ .95%
sUDhL-1 nuclei + .95%
karpas 299 nuclei heterogenous +/++ .50%
Jurkat nuclei ++ .90% 
Cem nuclei/cytoplasm ++ ,50% cells
b-cell
sUDhL-6 nuclei + .75%
sUDhL-10 nuclei ++ 90%
riVa nuclei + 20%
hLY-1  nuclei +/- 80% 
hBL-1 nuclei + 40%
thiel nuclei +/- 1% 
myeloid/megakaryotic
k562 nuclei/cytoplasm ++ ,95%
hL60 nuclei/cytoplasm ++ ,95%
U937 nuclei/cytoplasm ++ ,95%
heL nuclei/cytoplasm ++ ,95%
notes: *Cytoplasmic and nuclear intensity of labeling is as follows: 
++ = strong, + = moderate and +/- = weak, % refers to proportion of cells 
labeled. FePD – aLk-negative anaplastic large cell lymphoma; sUDhL-1 
and karpas 299 – aLk-positive anaplastic large cell lymphoma; Jurkat and 
Cem – t-acute lymphoblastic leukemia; sUDhL-6 and sUDhL-10 – germinal 
center-derived diffuse large B-cell lymphoma; riVa and hBL-1 – non-germinal 
center-derived diffuse large B-cell lymphoma; thiel – myeloma; k562 – 
chronic myeloid leukemia; U937 and hL60 – acute myeloid leukemia; heL – 
megakaryocytic-derived cell lines.
SUDHL-10, and nongerminal center RIVA and HBL-1 
(DLBC)-derived cell lines used were obtained and cultured 
as previously described.5 The cultured cells were used to pro-
duce cytocentrifuge preparations, cell pellets, or fixed in 10% 
formal-saline for paraffin embedding for the preparation of 
tissue sections of the cell lines.
Antibodies. Monoclonal antibodies: Mouse monoclonal 
antibodies to CD8 (C8/144), CD45RA (4KB5), and CD68 
(KP1) were produced in the authors’ laboratories. Antibodies 
to CD20 (Clone L26), cytokeratins (Clones Lp34 and Clones 
MNF116), and β-actin (diluted 1:100) were obtained from 
DakoCytomation (Glostrup, Denmark).
Polyclonal antibodies: A rabbit polyclonal antibody to 
FADD phosphorylated at Ser174 was obtained from Cell 
Signalling Technology (catalog number 2781, Cambridge, 
UK). Anti-CD3 (DAKO-CD3 – diluted 1:100), anti-mouse 
Ig conjugated to horseradish-peroxidase (HRP) diluted 1:100, 
and the Dako EnVision staining kit were obtained from 
DakoCytomation.
Immunolabeling techniques. Immunoperoxidase: Cyto-
centrifuge preparations and cryostat sections of tonsil were 
stained using a two-stage immunoperoxidase technique as 
previously described.5 Paraffin-embedded tissue sections 
and microarrays were de-waxed, and antigen retrieval was 
carried out in 50 mM Tris:2 mM EDTA pH 9.0 by micro-
wave pressure cooking for 2 minutes. The tissue sections were 
then incubated with a primary antibody for 60 minutes at 
room temperature (or in the case of anti-pFADD overnight 
at 4 oC) before being washed in phosphate-buffered saline 
(PBS) for 5 minutes. Antibody binding was detected using 
the ChemMateTM DAKO EnVisionTM Detection Kit, Peroxi-
dase/DAB using the manufacturer’s instructions. Cells were 
counterstained using hematoxylin and mounted in Aquamount 
(VWR International, Lutterworth, UK).
Double immunoperoxidase labeling: pFADD staining was 
performed as described above but with omission of the coun-
terstaining step. The sections were then incubated with one 
of the following: anti-CD3, anti-CD20, anti-cytokeratin, 
anti-CD8, or anti-CD68 for 30 minutes at room temperature 
before using the EnvisionTM anti-mouse/rabbit Dual Link 
reagent. After washing in PBS for 5 minutes, the slides were 
incubated with the vector SG Peroxidase (HRP) substrate kit 
(Vector Laboratories, Peter borough, UK). After washing, the 
slides were air-dried overnight and mounted in VectorMount 
(Vector Laboratories).
results
pFAdd distribution in normal tissues. The antibody 
recognizing pFADD has been used in a number of previous 
studies.22,26,34,35 Its use in the current study showed pFADD 
to have a limited nuclear distribution in normal tissues, as 
summarized in Table 1. Of particular interest was the dif-
ferential expression of pFADD in populations of hematopoi-
etic cells. High levels of pFADD were detected only in 
subpopulations of tonsillar germinal center and interfolli-
cular cells (Fig. 1A). Double labeling studies confirmed the 
majority of these cells to be CD20-positive B cells (Fig. 1B). 
In contrast, pFADD was undetectable in the majority of 
the CD3-positive T cells (Figs. 1C and D), with only low 
levels of pFADD observed in a minority of CD3-positive 
T cells. Although a small subpopulation of CD68-positive 
tingible body macrophages expressed pFADD (Fig. 1E), no 
interfollicular cells were observed that were stained for both 
pFADD and CD68 (Fig. 1F).
In the thymus, strong pFADD staining was limited to 
subsets of cells in the medulla and cortex (Fig. 1G). Double 
labeling studies showed only an occasional CD3-positive 
cell to be pFADD-positive, with the majority of CD3-
positive T cells lacking detectable pFADD (Fig. 1H, inset, 
arrowed). The remaining pFADD-positive cells included 
subpopulations of CD20-positive B cells (Fig. 1I), CD68-
positive macrophages (Fig. 1J) as well as thymic epithelial 
cells (Fig. 1K).
pFAdd expression in hematological malignancies. 
pFADD expression was also detected in T-cell derived as 
well as B-cell and myeloid-derived cell lines. The staining was 
FADD and pFADD in T-cell lymphomas
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nuclear and generally strong. Cytoplasmic staining was also 
seen in the myeloid (K562, HL60, and U937), megakaryocytic 
(HEL), and the T-acute lymphoblastic leukemia (Jurkat 
and CEM) cell lines tested. The results are summarized in 
Table 2.
A preliminary staining study was performed on mixed 
lymphoma TMAs, and the results are summarized in Table 3. 
pFADD proteins were detected across a range of B-cell lym-
phomas. Heterogeneity in the intensity of staining of pFADD 
was also seen both within and between cases of DLBCL and 
MCL (not shown).
In view of the importance of FADD in normal T-cell sur-
vival and proliferation,17 the previously reported expression of 
pFADD in a number of B-cell malignancies,34 and the presence 
of an anti-FADD immune response in patients with T-cell 
malignancies,7 we analyzed pFADD expression in 227 T-cell 
tumors, with particular emphasis on ALCL and PTCL (NOS). 
The results are shown in Table 3. Strong labeling of the tumor 
cells was observed in 32/38 (84%) ALK-positive and 45/54 
(83%) ALK-negative ALCL. Examples of results obtained 
are shown in Figures 2A and 2B. The numbers of tumor cells 
expressing pFADD varied from tumor biopsy to tumor biopsy 
(range 10%–99%). Moderate to weak pFADD labeling was 
also observed in other T-cell tumors. A total of 58/89 (65%) 
cases of PTCL (NOS) were positive for pFADD. Labeling of 
more than 30% of cells was detected in 9 (10%) of these cases 
while 49 (55%) cases showed less than 30% of the tumor cells 
to be pFADD-positive. pFADD expression was not detected 
in 31 (35%) cases of PTCL (NOS). Examples of staining are 
shown in Figures 2C–2E). Heterogeneity in the levels of stain-
ing of pFADD was observed within tumors in both ALCL 
and PTCL (NOS). pFADD expression was detected in a range 
of other T-cell lymphomas, including 67% (10/15) AITL, 57% 
(4/7) T-ALL, 50% (3/6) MF, and 66% (2/3) CTCL cases.
Additional evidence to support the dysregulation of 
FADD in T-cell tumors was obtained by analyzing levels 
of FADD transcripts from the publicly available Oncomine 
database (www.oncomine.org). Analysis of two independent 
gene expression profiling (GEP) datasets indicated that the 
FADD transcripts were significantly more highly expressed in 
T-cell lymphomas compared to nonmalignant T-cell popula-
tions (Fig. 3). Thus T-cell malignancies exhibit both elevated 
FADD transcription and FADD phosphorylation.
discussion
Although pFADD has been studied in a number of solid 
tumors, investigations of its expression in human hematological 
malignancies are limited. We previously used sera from ALCL 
Table 3. pFaDD expression in hematological malignancies.
ImmunOLAbELIng REsuLTs
TOTAL  
CAsEs
nEgATIvE ,30% POsITIvE CELLs
n (% TOTAL CAsEs)
.30% POsITIvE 
CELLs
n (% TOTAL CAsEs)
b-cell lymphomas
Diffuse large B-cell lymphoma 9 2 (22%) 4 (43%) 3 (33%)
mantle cell lymphoma 7 1 (14%) 4 (57%) 2 (29%)
Follicular lymphoma (n = 7) 7 4 (57%) 3 (43%) 0 (0%)
Burkitt lymphoma 6 3 (50%) 2 (33%) 1 (17%)
hodgkin’s lymphoma Lymphocyte predominant 3 0 (0%) 1 (33%) 2 (66%)
hodgkin’s lymphoma mixed cellularity 2 0 (0%) 0 (0%) 2 (100%)
hodgkin’s lymphoma nodular sclerosis 2 0 (0%) 0 (0%) 2 (100%)
hodgkin’s lymphoma Lymphocyte rich 3 0 (0%) 0 (0%) 3 (100%)
T-cell lymphomas
Peripheral t-cell lymphoma  
 (not otherwise specified) 
89 31 (35%) 49 (55%) 9 (10%)
aLk+ anaplastic large cell lymphoma 38 6 (16%) 8 (21%) 24 (63%)
aLk- anaplastic large cell lymphoma 54 9 (17%) 5 (9%) 40 (74%)
angioimmunoblastic lymphoma 15 5 (33.3%) 5 (33.3%) 5 (33.3%)
angiocentric lymphoma 5 0 (0%) 3 (60%) 2 (40%)
t lymphoblastic 7 3 (43%) 3 (43%) 1 (14%)
Cutaneous t-cell lymphoma 3 1 (33.5%) 2 (66.5%) 0 (0%)
mycosis Fungoides 6 3 (50%) 2 (33%) 1 (17%)
t/nk-cell lymphoma 2 0 (0%) 2 (100%) 0 (0%)
t-cell intestinal lymphoma 8 0 (0%) 3 (37%) 5 (63%)
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patients to screen a protein microarray containing more than 
12,000 different proteins with the aim of identifying lympho-
ma-associated antigens that could identify high-risk patients 
or that might represent novel therapeutic targets. Four anti-
gens, FADD, transcription elongation factor A protein-like 2 
(TCEAL2), lipid phosphate phosphate-related protein type 3 
(LPPR3), and ribonuclease T2 (RNASET2), were identified 
as ALK-negative ALCL-associated autoantigens. Further val-
idation studies also confirmed FADD, TCEAL2, and RNA-
SET2 to be PTCL-associated autoantigens recognized by 
circulating antibodies in patients.7 This result, combined with 
the interest in the role of pFADD in oncogenesis, indicated the 
importance of performing an immunohistochemical study of 
pFADD protein expression, in a range of T-cell lymphomas.
High levels of pFADD protein had a limited distribu-
tion in normal tissues and were restricted to the nucleus. These 
results are in agreement with previous studies reporting nuclear 
pFADD protein in subpopulations of human gastric epithelial 
cells, hepatocytes, kidney, and tonsillar cells.28,29,34,36 The cur-
rent study using double labeling techniques is, however, the 
first not only to confirm high levels of pFADD expression 
in subpopulations of normal CD20-positive B cells but also 
to identify the absence or restricted low-level expression of 
pFADD in normal tonsillar T cells and thymocytes. Since the 
presence of pFADD has been linked to T-cell activation and 
proliferation in human cell lines and in mice,17,18,37 the lack of 
pFADD in T cells in the current study suggests that there are 
only low numbers of activated T cells in the G2/M stage of 
cell cycle in normal tonsil and thymus.
pFADD was observed in B-cell-derived cell lines and 
tumors, a result in keeping with a previous study where 
pFADD expression was found to correlate with the prolifera-
tion of B-lymphoma cells.34 pFADD expression was, however, 
also detected in a wide variety of T-cell leukemia-derived cell 
lines and in primary T-cell lymphoma biopsies. 65% PTCL 
(NOS) and 83% ALCL expressed levels of pFADD. No signif-
icant difference was found between ALK-positive and ALK-
negative ALCL, with high levels of pFADD being detected 
in 84% and 83% of ALK-positive and ALK-negative ALCL, 
respectively. Although pFADD protein expression was previ-
ously reported in ALCL and CTCL, Clarke et al investigated 
only nine cases of ALCL and three cases of CTCL.36 The 
increased expression of pFADD protein in T-cell malignan-
cies compared to normal T-cells studied here suggests that 
pFADD is accumulated possibly as a result of the constitutive 
activation of the tumor cells. The increase in pFADD could 
also result from increased expression of FADD or its increased 
phosphorylation as part of the disease process. The evidence 
A
C D E
BALK-positive ALCL
PTCL PTCL PTCL
ALK-negative ALCL
ALK-positive ALCL
Figure 2. single immunoperoxidase labeling demonstrating pFaDD expression in aLCL and PtCL (nos).  
notes: (A) an example of a case of aLk-positive aLCL where the tumor cells express pFaDD (arrowed). note the presence of pFaDD in the cytoplasm 
of mitotic cells (arrowhead). the inset shows an example of a pFaDD-negative case of aLk-positive aLCL. (b) strong nuclear pFaDD expression is also 
present in a case of aLk-negative aLCL (arrowed). Cytoplasmic pFaDD is also present in a mitotic cell (arrowhead). Different examples of pFaDD in 
three cases of PtCL are shown in (C–E). While the majority of tumor cells are pFaDD-positive (arrowed) in (C), the percentage drops to less than 30% in 
(D) while the PtCL in (E) lacks detectable pFaDD.
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other studies. Increased levels of pFADD and NF-κΒ have 
been linked to poorer survival in head and neck26 and lung 
cancers,22,28 while others have described low pFADD expres-
sion to be associated with poorer prognosis in myeloid leuke-
mia.47 There is also a reported link between higher levels of 
pFADD and improved local tumor control in early stage larynx 
cancer27 and prostate cancer.20 Of interest is that the increased 
transition from FADD to pFADD has been associated with an 
improved sensitivity to treatment with chemotherapy in pros-
tate cancer23,30 and radiotherapy in head and neck cancer.27
Although ALK-positive ALCL is associated with a 
good prognosis,48 the same cannot be said for ALK-negative 
ALCL and PTCL-NOS, and improved therapies are urgently 
needed for these lymphomas.49–52 FADD and its interacting 
proteins, such as RIP1, are expressed in both ALK-negative 
and ALK-positive ALCL53 and may thus represent exciting 
therapeutic targets. Although there is evidence for a tumor 
suppressor role of pFADD in nonhematological tumors,31 
it will be important to study further the biological activity 
of pFADD in T-cell malignancies. Of interest was a report 
that a novel inhibitor of FADD phosphorylation resulted in 
decreased levels of the anti-apoptotic NF-κΒ,44 a factor impli-
cated in lymphogenesis,54 suggesting the potential of pFADD 
as a therapeutic target in T-cell malignancies.
In conclusion, the results from the current study provide 
the first detailed immunohistochemical study of the expres-
sion of pFADD in normal tissues and hematological malig-
nancies, with particular emphasis on T-cell tumors. The 
increased expression of pFADD observed in T-cell lymphomas 
not only suggests a possible role in lymphoma development 
but also further highlights phosphorylation of the lympho-
ma-associated autoantigen FADD as a potential therapeutic 
target.
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Figure 3. FADD transcript expression in t-cell lymphomas and aLCL. 
notes: FADD transcript was expressed at significantly higher 
levels in t-cell lymphomas than in nonmalignant t-cell populations 
in two independent gene expression profiling datasets: (A) normal 
t-lymphocytes, n = 31; aLCL (anaplastic large cell lymphoma), n = 9  
(five cases of ALK-positive ALCL and four cases of ALK-negative 
aLCL);38 and (b) normal t-lymphocytes, n = 20 (including five samples 
each of CD4-positive and CD8-positive t-lymphocytes); aLCL, n = 6; 
aitL (angioimmunoblastic t-cell lymphoma), n = 6; PtCL (nos) 
(peripheral T-cell lymphoma, not otherwise specified), n = 28.8
from two GEP datasets8,38 (shown in Fig. 3), where increased 
levels of FADD transcripts were observed in PTCL, AITL, 
ALK-positive and ALK-negative ALCL, compared to normal 
T cells, suggests that the increased pFADD protein expression 
in some patients is likely to reflect the upregulation of FADD 
transcription and thus, most likely, increased FADD protein.
A major factor in lymphoma growth is resistance to apopto-
sis. Examples include abnormalities in the Fas/FasL and CD30-
mediated apoptotic pathways as well as c-FLIP overexpression 
in T-cell lymphomas such as ALK-positive ALCL,39 and ALK-
negative tumors such as CTCL and mycosis fungoides.40,41 It is 
possible that re-localization of FADD to the nucleus following its 
phosphorylation19,42 may play a major role in the dysregulation of 
apoptosis in human lymphomas as reported for murine T-ALL.43 
pFADD overexpression has also been linked to increased activ-
ity of the anti-apoptotic NF-κB protein.22,44 and activation of 
the c-jun NH2-terminal kinase (JNK) signaling pathway,24,30 
both of which are implicated in T-cell lymphomagenesis.45,46 
Aberrant pFADD expression has also been linked with prolif-
eration in human B-cell lymphomas34 and to cell cycle defects in 
murine T cells,37 with hematopoietic as well as solid tumor cells 
arresting at the G2/M stage.18,19,23,24
Further investigations are required to determine the prog-
nostic relevance of pFADD in T-cell malignancies, which 
has been linked with varying outcomes in malignancies in 
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